Tiziana stock pops on plans to develop intranasal foralumab for Long COVID
BeritK/iStock via Getty Images
- Tiziana Life Sciences (NASDAQ:TLSA) plans to investigate intranasal foralumab to treat Long COVID.
- The company said the work is supported by foralumab's established role in de-activating microglia cells, a component in the pathogenesis of the disease.
- "We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA," said Tiziana's Chief Medical Officer Matthew Davis. "The use of PET Scans will allow us to determine if intranasal foralumab will decrease activated microglia in patients with Long COVID after 3 months of administration."
- Davis noted that after refining clinical protocols, the company needs to discuss the approach with the FDA and plan to file an IND in Q4 2023.
- TLSA +4.90% to $1.07 premarket April 13